HEPA
Hepion Pharmaceuticals
HEPA
HEPA
Delisted
HEPA was delisted on the 12th of May, 2025.
25 hedge funds and large institutions have $3.61M invested in Hepion Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Holders
25
Holding in Top 10
–
Calls
$97K
Puts
$8K
Top Buyers
| 1 | +$43.4K | |
| 2 | +$27.5K | |
| 3 | +$17.1K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$13.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.72K |
Top Sellers
| 1 | -$235K | |
| 2 | -$26K | |
| 3 | -$23K | |
| 4 |
BlackRock
New York
|
-$13.4K |
| 5 |
Two Sigma Advisers
New York
|
-$9.77K |